The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer ...

The mid-stage IMscin002 study showed that 71% of patients preferred Tecentriq Hybreza over IV infusion. The new SC option ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

This means Tecentriq still needs a discount of 31%-53% from the wholesale acquisition cost list price in order for it to be considered cost effective. For Opdivo, this is 57-68%, with Keytruda ...

Market volatility in Q3 was driven by softer-than-expected US employment data, but resilient earnings and rate cuts led to a ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Roche has produced new data showing a combination of Tecentriq and older drug Avastin is more effective than standard therapy for delaying progression in kidney cancer patients. The company’s ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) is celebrating the FDA approval of Roche's Tecentriq Hybreza™ with its drug delivery technology ENHANZE® for multiple types of cancer. Tecentriq ...

“In the quarter, the announcement of two highly anticipated partner approvals in the U.S. for Roche’s TECENTRIQ HYBREZA and OCREVUS ZUNOVO reinforces ENHANZE’s track record of 100% phase 3 ...